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care: a systematic review of systematic reviews
Abstract
Background There has been growing interest regarding the impact of telemonitoring and its ability to reduce
the increasing burden of chronic diseases, including chronic cardiovascular disease (CVD), on healthcare
systems. A number of randomised trials have been undertaken internationally and synthesised into various
systematic reviews to establish an evidence base for this model of care. This study sought to synthesise and
critically evaluate this large body of evidence to inform clinicians, researchers and policy makers. Methods A
systematic review of systematic reviews investigating the impact of telemonitoring interventions in the
primary care management of CVD was conducted. Reviews were included if they explored primary care based
telemonitoring in either CVD, heart failure or hypertension, were reported in the English language and were
published between 2000 and 2013. Data was extracted by one reviewer and checked by a second reviewer
using a standardised form. Two assessors then rated the quality of each review using the Overview Quality
Assessment Questionnaire (OQAQ). Results Of the 13 included reviews, four focused on telemonitoring
interventions in hypertension or CVD management and the remaining 9 reviews investigated telemonitoring
in HF management. Seven reviews scored a five or above on the OQAQ evidencing good quality reviews.
Findings suggest that telemonitoring can contribute to significant reductions in blood pressure, decreased all-
cause and HF related hospitalisations, reduced all-cause mortality and improved quality of life.
Telemonitoring was also demonstrated to reduce health care costs and appears acceptable to patients.
Conclusion Telemonitoring has the potential to enhance primary care management of CVD by improving
patient outcomes and reducing health costs. However, further research needs to explore the specific elements
of telemonitoring interventions to determine the relative value of the various elements. Additionally, the ways
in which telemonitoring care improves health outcomes needs to be further explored to understand the nature
of these interventions.
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Abstract
Background: There has been growing interest regarding the impact of telemonitoring and its ability to reduce the
increasing burden of chronic diseases, including chronic cardiovascular disease (CVD), on healthcare systems. A
number of randomised trials have been undertaken internationally and synthesised into various systematic reviews
to establish an evidence base for this model of care. This study sought to synthesise and critically evaluate this
large body of evidence to inform clinicians, researchers and policy makers.
Methods: A systematic review of systematic reviews investigating the impact of telemonitoring interventions in the
primary care management of CVD was conducted. Reviews were included if they explored primary care based
telemonitoring in either CVD, heart failure or hypertension, were reported in the English language and were
published between 2000 and 2013. Data was extracted by one reviewer and checked by a second reviewer using a
standardised form. Two assessors then rated the quality of each review using the Overview Quality Assessment
Questionnaire (OQAQ).
Results: Of the 13 included reviews, four focused on telemonitoring interventions in hypertension or CVD
management and the remaining 9 reviews investigated telemonitoring in HF management. Seven reviews scored a
five or above on the OQAQ evidencing good quality reviews. Findings suggest that telemonitoring can contribute
to significant reductions in blood pressure, decreased all-cause and HF related hospitalisations, reduced all-cause
mortality and improved quality of life. Telemonitoring was also demonstrated to reduce health care costs and
appears acceptable to patients.
Conclusion: Telemonitoring has the potential to enhance primary care management of CVD by improving patient
outcomes and reducing health costs. However, further research needs to explore the specific elements of
telemonitoring interventions to determine the relative value of the various elements. Additionally, the ways in
which telemonitoring care improves health outcomes needs to be further explored to understand the nature of
these interventions.
Keywords: Systematic review, Telemonitoring, Heart failure, Hypertension, Primary care
* Correspondence: ehalcomb@uow.edu.au
2School of Nursing & Midwifery, University of Wollongong, Wollongong,
NSW, Australia
Full list of author information is available at the end of the article
© 2014 Purcell et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Purcell et al. BMC Family Practice 2014, 15:43
http://www.biomedcentral.com/1471-2296/15/43
Background
The growing burden of the group of diseases that comprise
cardiovascular disease (CVD) on national healthcare sys-
tems is well recognised amongst healthcare professionals
internationally. Despite a trend towards decreasing mortal-
ity, CVD remains the major cause of death worldwide [1].
In Australia, CVD accounts for a greater proportion of
deaths than any other disease group, and accounts for the
highest proportion of direct health care expenditure [2].
Improved acute care, advanced intervention techniques,
early diagnostic procedures, and worldwide demographic
ageing have resulted in an increasing number of patients
living with chronic CVD [3,4]. As a result, chronic heart
failure (HF) is becoming an increasing health issue [5]. Al-
most half the individuals admitted to hospital for HF are
re-admitted within 6 months [6,7]. These frequent hospital
re-admissions contribute significantly to the high costs of
HF management [6,7]. Up to 70% of HF cases, are preceded
by hypertension [5]. Implementation of evidence based
hypertension management has the potential to reduce the
prevalence of HF and, subsequently, reduce HF burden.
Given the interrelationship and progressive nature of car-
diac disease in primary care, there are advantages in consid-
ering the impact of management strategies across the
disease silos.
The increasing burden associated with CVD neces-
sitates the investigation of innovative models to
provide evidence-based care to promote early identifi-
cation of exacerbations and early intervention to min-
imise their severity. Among the available models is
telemonitoring, which consists of remote monitoring
of patients to enable clinicians to intervene when
there is evidence of clinical deterioration in an
attempt to avoid hospitalisation [8]. Telemonitoring
moves patient care out of a clinical setting into
the patient’s home by utilising telecommunications
technologies such as the Internet, telephone, or vid-
eoconferencing to transmit physiological data and in-
formation about current symptoms from the patient
to health care professionals [8]. Shifting the burden of
care to the patient’s home also facilitates supported
self-care, giving the patient enhanced autonomy and
control of their health care [8]. Telemonitoring pro-
grams can be flexible, individually tailored, and have
the potential to provide access to specialist care for a
larger number of patients across a much greater
geography when compared to usual care [8-10].
Currently the literature reports multiple systematic re-
views investigating the effectiveness of telemonitoring in
both HF and its antecedent, hypertension. Given the large
amount of literature available, a systematic review of re-
views was conducted to synthesise and critically evaluate
this current Level 1 evidence around the use of telemoni-
toring in the primary care setting.
Methods
This review was conducted using the Preferred Reporting
Items of Systematic Reviews Meta-Analyses (PRISMA)
guidelines [11]. A systematic review design was selected to
limit any bias in the selection and reporting of evidence.
Search strategy
A comprehensive and systematic search was undertaken
using CINAHL, MEDLINE and the Cochrane Library
electronic databases. The search strategy included the
Medical Subject Headings (MeSH) terms; telehealth,
telemedicine, heart failure, hypertension, cardiovascular
disease and systematic review. As a relatively new form
of technology, reviews were retrieved if they were pub-
lished between 2000 and 2013. Secondary searching of
the reference lists of retrieved papers and of the Internet
via the Google scholar search engine was undertaken to
identify any additional reviews that met the inclusion
criteria.
Selection procedures
Papers were retrieved based on whether the title and ab-
stract or, if required, the full manuscript met the inclusion
criteria for this review. Papers identified through the search
were assessed based on the inclusion and exclusion criteria
by two independent reviewers (RP and EH). Where there
was discrepancy, the reviewers discussed the issues and
reached consensus.
Inclusion criteria
Systematic reviews were included if they met the follow-
ing inclusion criteria. Firstly, the paper needed to report
a systematic review or meta-analysis of original interven-
tion studies. Reviews that did not meet the definition of
a systematic review or meta-analysis, or were expert
commentaries were not included [8]. Secondly, included
reviews needed to explore the impact of telemonitoring
on the health outcomes of adults with known CVD as
distinct from those with other chronic diseases. An a
priori decision was made to not include studies with
paediatric samples. Thirdly, given the focus on telemoni-
toring as distinct from home monitoring, reviews were
excluded if there was no evidence that home based mea-
sures were transmitted to a healthcare provider. Finally,
due to resource constraints and ease of access, reviews
that were published in any language other than English,
or reviews that were unpublished were excluded from
the analysis.
Data extraction
Two authors (RP and EH) developed a standardised form
for extracting data and relevant information from the 13 in-
cluded reviews. Whilst developed specifically for this re-
view, the form was based on tools used in other systematic
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reviews and systematic reviews of reviews [12,13]. The form
contained 10 categories regarding the characteristics and
results of the included reviews. All data were initially ex-
tracted by one author (RP), this extraction was then
checked by a second author (EH) for accuracy. Where dif-
ferences were identified, the authors discussed issues and
reached a consensus decision.
Methodological quality
A two-stage process was undertaken to evaluate both the
type of evidence contained in each included review, and the
quality of the review process used. In the first stage of this
process, the level of evidence was graded using the National
Health & Medical Research Council (NHMRC) hierarchy
(Table 1). Whilst systematic reviews of randomised con-
trolled trials are considered the highest level of evidence on
this hierarchy, other reviews are ranked only as high as
their included studies [14].
In the second stage of this process, the quality of in-
cluded systematic reviews and meta-analyses were
assessed using the component and total scores from the
Overview Quality Assessment Questionnaire (OQAQ).
The OQAQ has been previously validated as a measure
of quality in research reviews [15,16]. Two reviewers in-
dependently scored each paper using OQAQ (RP and
SM) and any disparities were discussed with a third re-
viewer (EH) until consensus was reached.
Results
Ninety-nine papers were identified by the search strategy
and assessed against the review inclusion criteria. All re-
viewers agreed that 13 papers met the inclusion criteria for
the review. Papers were excluded if they did not distinguish
individuals with CVD from those in other disease groups,
the intervention did not involve information transmission
between the consumer and health provider or did not re-
port a formal systematic review (references to these papers
can be provided on request). The flowchart in Figure 1 out-
lines the process for selecting included papers.
Of the 13 included reviews, nine were graded as Level 1
on the NHMRC Hierarchy [8,10,17-23]. The remaining re-
views included a combination of RCTs, observational, de-
scriptive, case series and/or non-randomised controlled
studies, therefore, were considered to be Level II to IV
evidence [24-27]. Seven reviews [8,10,17,18,23,26,28] scored
five or above on OQAQ, indicating minor or no methodo-
logical flaws [15] (Table 2). Reviews that failed to score
above a five predominantly did so due to the poor assess-
ment of validity in primary studies and/or the authors fail-
ing to use a validated quality scoring system. The quality
features of included systematic reviews are presented in
Table 2.
As can be seen in Tables 3 and 4, 9 reviews investi-
gated telemonitoring for heart failure [8,10,21-27], three
focused on telemonitoring interventions for hyperten-
sion [17,19,20] and a single review looked at risk factor
reduction in CVD [18]. The number of studies synthe-
sised in the included reviews varied between 9 [20,21]
and 56 [25] studies. Whilst the number of included par-
ticipants was not accurately reported in two reviews
[24,26], in the remaining reviews the number of partici-
pants ranged from 2,401 to 9,946 [8,10,17-22,25,27,28].
Definitions of telemonitoring varied, with some re-
views of hypertension management only citing studies
that used telemonitoring to transmit physiological data
[20,22] and other reviews included studies of telemoni-
toring combined with additional support, such as coun-
selling, and/or education [8,10,17-19,21,24-28]. In some
reviews it was possible to compare outcomes between
various types of interventions [8,21,25], whilst in others
various interventions were combined in the analysis
[23]. This variation is a reflection of the current state of
the literature and the significant variety of operational
definitions of telemonitoring between studies included
in the reviews.
A diverse range of outcomes was measured across the
reviews. Those reviews which investigated hypertension
primarily used blood pressure and medication use as
outcomes (Table 3), whilst those investigating HF used a
combination of outcomes including, mortality, hospital
admissions, quality of life, cost, acceptability (Table 4).
All reviews reported benefits associated with telemoni-
toring, however the significance of the identified benefits
differed between studies and reviews. No review re-
ported negative effects of telemonitoring or harm to pa-
tients. All reviews noted significant variance between
included studies with four reviews citing statistically sig-
nificant heterogeneity [8,18,19]. It is essential that this
be considered in the interpretation of these data.
Synthesis of reviews of hypertension & CVD management
Table 3 provides a summary of the four included reviews
that focused on telemonitoring in hypertension and
CVD management.
Blood pressure
The four reviews which investigated hypertension and
CVD management all used blood pressure as an outcome




I Systematic review of randomised controlled trials
II Randomised controlled trial
III Pseudo-randomised controlled trial, comparative study
with or without concurrent controls
IV Case series with either post-test or pre-test/post-test
outcomes
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measure [17-20]. The operational definition of blood pres-
sure differed across reviews with all reviews reporting sys-
tolic blood pressure [17-20], three reporting diastolic
pressure [17,19,20], one review reporting mean arterial
pressure [17] and another reporting blood pressure normal-
isation [19]. All reviews reported significant reductions in
blood pressure with the various interventions (Table 3).
Given the concomitant changes in extraneous variables
such as medication use and lifestyle risk factors that oc-
curred around the interventions, it is difficult to ascertain
which specific aspects of the intervention led to the im-
provements in blood pressure seen within these reviews
and included studies.
Medication use
Three reviews which investigated hypertension and CVD
management reported medication use as an outcome meas-
ure [17,19,20]. There was some variation in finding of
medication use between reviews. Agarwal et al. [17] re-
ported that 10 studies demonstrated reduced medication
use (RR 2.02, 95% CI 1.32 to 3.11) and 12 studies reported
no greater increase in medication (RR 0.94, 95% CI 0.75 to
1.19). In contrast, Omboni & Guarda [19] reported five
studies that demonstrated increased use of antihypertensive
medications (WMD +0.22, 95% CI: +0.02, +0.43). It should
be noted that this increase in antihypertensive use may have
been a positive finding if patients had been sub-optimally
medicated and were now receiving best practice
pharmacotherapy.
In their review, Verberk et al. [20] compared the
outcomes of those who had their antihypertensive
treatment modified and those who did not have
modified treatment during the study in both the
intervention and treatment groups. This comparison
demonstrated that treatment modification was associated
with significantly lower systolic BP compared to non-
modification (5.1 mmHg ± 2.9 mmHg lower).
Synthesis of reviews of heart failure management
Table 4 provides a summary of the nine included reviews
that focused on telemonitoring in HF management.
Hospital admission
Eight of the reviews of HF management used hospitalisa-
tion as an outcome measure [8,10,21-26]. All these reviews
reported that telemonitoring was associated with reduced
hospitalisations [8,10,21-27]. The reduction in hospitalisa-
tion was reportedly as high as 50% in one review [21].
However, three reviews reported included studies that did
not demonstrate a statistically significant reduction in
hospitalisation rates [10,21,22]. Indeed in their review,
Giamouzis et al. [22] identified four included studies in
which the telemonitoring group had more rehospitalisation’s
than the usual care group, although these findings were
either non-significant or the significance was not reported.
In terms of HF related hospitalisations, Inglis et al. [8] re-
ported that both telemonitoring and structured telephone
support reduced the number of patients having a HF re-
lated admission to hospital (structured telephone support
RR 0.77, 95% CI 0.68 to 0.87, P < 0.0001 and telemonitoring
RR 0.79, 95% CI 0.67 to 0.94, P = 0.008). Similarly,
Chaudhry et al. [21] found that both video conferencing
and regular nurse phone calls reduced 6-month HF related
admissions to hospital compared to usual care. However,
there were no between group differences between video
conferencing and regular nurse support.
Length of stay
Length of stay (LOS) was reported as an outcome in five
included reviews [8,23-26]. However, in three of these
Figure 1 Process of review selection.
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Search methods used to find evidence stated 3 1 3 3 3 3 3 2 3 3 3 2 3
Search for evidence reasonably
comprehensive
3 3 3 2 2 2 2 2 2 2 2 2 2
Criteria used for deciding which studies to
include reported
3 3 3 2 3 2 2 3 3 3 2 3 3
Bias in the selection of studies avoided 3 3 3 2 3 3 2 3 3 3 2 3 3
Criteria used for assessing validity of
included studies reported
3 3 3 3 2 2 2 1 1 1 1 1 1
Validity of included studies assessed
appropriately
3 3 2 3 2 2 2 1 1 1 1 1 1
Methods used to combine the findings of
studies reported
3 3 3 3 3 3 3 2 3 3 2 2 3
Findings of studies combined appropriately 3 3 3 3 3 3 3 2 3 3 2 2 2
Conclusions made by authors supported by
analysis
3 3 3 3 3 3 2 3 3 2 3 2 3






























Intervention Outcomes Results Conclusion
Agarwal
et al. [17]




compared to a control
group.




Compared with clinic based
measurements, home based BP
monitoring;
• Improved systolic BP (SMD −2.63
mmHg, 95% CI −4.24 to −1.02; 22
studies)
• Improved diastolic BP (SMD -
1.68 mmHg, 95% CI −2.58
to −0.79 mmHg; 22 studies)
• Improved mean arterial pressure
(SMD −4.0 mmHg, 95% CI −6.22
to −1.79 mmHg; 3 studies)
• Reduced medication use (RR 2.02,
95% CI 1.32 to 3.11; 10 studies)
• Reduced therapeutic inertia (RR 0.82,
95% CI 0.68 to 0.99; 15 studies)
• Led to no greater increase in
medication (RR 0.94, 95% CI 0.75
to 1.19; 12 studies)
• Compared with clinic BP
monitoring alone, home BP
monitoring had the potential to
overcome therapeutic inertia
[no change in medication].
• Lead to a small but significant
reduction in systolic and
diastolic BP.
• Hypertension management
with home BP monitoring can



























• Quality of life
• Cost
Compared to the control group the
evidence suggests that the intervention
group had;
• Reduced total cholesterol (WMD
0.37 mmol/L, 95% CI: 0.19 to 0.56,
9 studies)
• Reduced low-density lipoprotein chol
esterol (WMD 0.41 mmol/L, 95% CI:
0.36 to 0.56, 4 studies)
• Reduced systolic blood pressure
(WMD 4.69 mmHg, 95% CI 2.91 to 6.47,
7 studies)
• Reduced risk of smoking (RR 0.83,
95% CI: 0.70 to 0.99, 7 studies)
• Telemonitoring interventions
provided effective risk factor
reduction and secondary
prevention in patients with CHD.
• Telemonitoring could increase
the uptake of formal secondary
prevention by those who do not
access cardiac rehabilitation, and

























Compared to controls the overall
effect of home BP monitoring was;
• Improved office systolic BP (5.64 mm
Hg, 95% CI: 7.92 to 3.36 mm Hg,
11 studies)
• Improved office diastolic BP (2.78
mm Hg, 95% CI: 3.93 to 1.62 mm
Hg, 11studies)
• Improved ambulatory systolic BP
(2.28 mm Hg, 95% CI: 4.32
to 0.24 mm Hg; 3 studies)
• Improvement in BP control (RR
1.31, 95% CI: 1.06 1.62, 5 studies)
• Home blood pressure
telemonitoring may represent a
useful tool to improve blood
pressure control but well-
designed large-scale trials are still



















Table 3 Summary table of included reviews - hypertension (Continued)
• Increased use of antihypertensive
medications (WMD +0.22, 95%
CI: +0.02, +0.43, 5 studies)
Verberk
et al. [20]






Home BP transmitted via
telephone, internet,
modem or mail.
• BP - diastolic,
systolic
• Medication
Compared with usual care, home
based BP monitoring;
• Reduced systolic BP (5.19 mmHg, 95%
CI 2.31 to 8.07; 9 studies)
• Reduced diastolic BP (2.11 mmHg,
95% CI 0.52 to 3.69; 9 studies)
• There was no significant difference
between groups in the number of
patients that reached their target blood
pressure (3 studies)
• Telecare led to a greater
decrease in systolic and diastolic
blood pressure than usual care.
For systolic blood pressure, this



























Inclusion criteria Intervention Outcomes Results
Chaudhry
et al. [21]





analysis) – 5 studies
Automated monitoring of
signs & symptoms – 1 study
Automated physiological
monitoring – 1 study
Comparisons of two or
more methods of
telemonitoring
(no meta-analysis) – 2 studies
• All cause and
HF mortality
• All cause and H
F admissions
• Cost
• Reduced all-cause hospitalisation (47%) (1 study)
• Reduced HF hospitalisations (2 studies) (20-50%
reduction)
• No significant difference in HF hospitalisations
(2 studies)
• Reduced emergency room visits (95% CI 0.36-0.80)
(1 study)
• Reduced mortality (1 study)
• Reduced health care costs ($1000 less per patient)
(1 study)
• No significant difference in all-cause hospitalisations
(1 study)
• Reduced mortality (56% - 95% CI 0.22-0.85) (1 study)
• Reduced HF hospitalisations (1 study) (40% - 95%
CI 0.45-0.82)
• Reduced health care costs ($276705 less 6-month
cumulative readmission charges in the intervention
group) (1 study)
• Both physiologic monitoring and regular nurse
telephone calls showed improved mortality and
hospitalisation rates compared to usual care
(1 study).
• No between group differences in mortality and
hospitalisation rates between physiologic monitoring
and regular nurse telephone calls (12.7% vs 15.9%)
(1 study).
• Both video conferencing and nursing support by
telephone showed reduced 6-month HF readmission
charges compared to usual care (1 study).
• No between group differences in 6-month HF
readmission charges were seen between video










support – 9 studies
Telemonitoring and structured








• Both interventions were associated with a
statistically significant 20% reduction in all-cause
mortality (RR 0.80, 95% CI: 0.69 to 0.92; 14 studies)
• A decrease in all-cause mortality was more
pronounced with telemonitoring (RR 0.62, 95% CI: 0.45
to 0.85; 4 studies) than with structured telephone
support (RR 0.85, 95% CI: 0.72 to 1.01; 9 studies)
• HF related hospitalisation was significantly reduced
by 20% through remote monitoring programmes
(RR 0.79, 95% CI 11%-31%).
• None of the 8 studies that reported all cause
admission to hospital reported a statistically



















Table 4 Summary table of included reviews – heart failure (Continued)
• 3/6 trials that investigated quality of life reported a
significant and substantial improvement.
• 3/4 trials of structured telephone support reported
lower healthcare costs.








• Follow-up of at least
6 months




physiological data by portable devices, and







Compared to controls the telemonitoring groups
had:
• Reduced hospitalisation rates that reached
statistical significance (3 studies)
• Reduced hospitalisation rates without reaching
statistical significance (4 studies).
• Statistically significant reduced all-cause mortality
(3 studies).
• Fewer reported deaths, however these results were
not statistically significant (5 studies)
• Evidence for costs associated with telemonitoring
were mixed with two studies finding cost reductions
and one study finding increased costs.
• In four studies there were more re-hospitalisations
in telemonitoring groups compared to usual care
groups, but these findings were either not statistically
significant or significance was not reported.
Inglis et al.
[8]
I 25 8323 • Published between
1999 – 2008
Telemonitoring (transfer of daily data) – 11
studies
Structured Telephone support – 16 studies








• Length of stay
• Telemonitoring reduced all-cause mortality (RR 0.66,
95% CI: 0.54–0.81; 11 studies)
• Structured telephone support showed a non-
significant trend towards reduced all-cause mortality
(RR 0.88 95% CI: 0.76– 1.01; 15 studies)
• Both telemonitoring (RR 0.79, 95% CI: 0.67–0.94;
4 studies), and structured telephone support (RR 0.77,
95% CI 0.68–0.87; 13 studies) reduced chronic heart
failure related hospitalisations
• Both interventions improved quality of life, reduced
costs, and were acceptable to patients
• 1/6 studies reported a statistically significant
reduction in length of stay, with a further 2 studies
reporting a non-significant reduction
Klersy
et al. [23]





Either structured telephone monitoring or
technology assisted monitoring –





• Quality of life
• Remote patient monitoring was associated with
significantly fewer hospitalizations for HF (incidence
rate ratio: 0.77, 95% CI 0.65–0.91, P < 0.001) (18 studies)
• Remote patient monitoring was associated with
significantly fewer hospitalizations for any cause
(incidence rate ratio: 0.87, 95% CI: 0.79–0.96,
P = 0.003) (18 studies)
• LOS was not different between remote patient
monitoring and usual care for either HF
hospitalisations (95% CI 20.12–0.13, P = 0.88) or
all-cause hospitalisation (95% CI 20.18–0.02, P = 0.83)
(12 studies).


















Table 4 Summary table of included reviews – heart failure (Continued)
• RPM was associated with a gain of 0.06 quality-
adjusted life years – 0.02 due to reduced mortality









Home monitoring using specialised devices




• Length of stay





Observational studies suggested that telemonitoring:
• Reduced hospitalisation (10 studies) and
readmission rates (2 studies)
• Reduced length of stay (4 studies)
• Reduced ED presentations (2 studies)
• Reduced inpatient costs (1 study)
• Was acceptable to patients (3 studies), patients
were highly satisfied (>86%)(2 studies) and improved
quality of life (1 study).
Compared with usual care telemonitoring RCTs:
• Reduced hospitalisation (2 studies) and readmission
rates (1 study)
• Reduced mortality (1 study)
• Reduced length of stay (1 study)




IV2 56 – • English language
• Published before
August 2007
Device-based technologies - 16 studies
Telephone touch-pads - 12 studies
Video-consultation-based studies - 3 studies
Website-based telemonitoring - 5 studies
Combined modalities - 21
• Hospitalisation
• Quality of life
• Medication
• Cost
• Length of stay
• Decreased hospitalizations (8 studies)
• Improved QOL (5 studies)
• Fewer re-hospitalizations and combined events
(1 study)
• Reduced time to target drug dosage (1 study)
• No significant changes (1 study)
• Change in mood (1 study)
• Improved QOL (1 study)
• Reduced hospital length of stay (1 study)
• Increased hospital length of stay (1 study)
• Decreased hospitalizations (7 studies)
• Reduced costs (6 studies)




Home monitoring of HF patients using







• Length of stay
• Quality of life
• Feasibility/viability
Compared to the control groups the evidence
suggests that telemonitoring;
• Improved quality of life (12 studies)
• Reduced length of hospitalisation (12 studies)
• Reduced mortality (4 studies)
• Reduced costs (9 studies)
• Reduced unattended emergencies (1 study)























Table 4 Summary table of included reviews – heart failure (Continued)
Seto [27] III4 10 586 • English language
• Published between
inception – April 2010
Telemonitoring systems with a component
of home physiological measurements.
• Cost • 9/10 studies analysed direct healthcare system
costs. 1/10 study investigated direct patient costs.
• All the studies found cost reductions from
telemonitoring compared to usual care, ranging
between 1.6% and 68.3%
• Cost reductions were predominantly attributed to
reduced hospitalisation expenditures.
• A 3.5% lower direct patient costs was identified,
related to patient travelling.
• 55% of patients were willing to pay $20 to use
telemedicine and 19% were willing to pay $40.
1RCT– 6 studies, Non-randomised – 12 studies, Observational- 6 studies.
2RCT- 23 Studies, Non Randomised – 10 Studies, Pre-post – 15 Studies, Feasibility – 1 Study, Unknown design – 8.
3RCT – 13 studies, Non-randomised – 10 studies, Clinical series or descriptive studies – 19 studies.


















reviews, fewer than six included studies reported LOS as
an outcome [8,24,25]. In these three reviews all but one
study reported reduced length of hospital stay following
the intervention [25].
The other two reviews included 12 studies each that
reported LOS as an outcome, although had conflicting
findings. The recent review published by Klersy [23]
concluded that length of stay was not different between
remote patient monitoring (combined telemonitoring
and structured telephone support) and usual care for ei-
ther HF (95% CI 20.12–0.13, P = 0.88) or all-cause hospi-
talisation (95% CI 20.18–0.02, P = 0.83). However, the
older review by Martínez et al. [26] reported that tele-
monitoring reduced length of hospitalisation.
Mortality
Six reviews of HF management used all-cause mortality as
an outcome measure [8,10,21,22,24,26]. As can be seen
from Table 5, a range of interventions improved mortality.
In their comparative reviews, both Clark et al. [10] and
Inglis et al. [8] demonstrated that all-cause mortality was
more significantly reduced in studies using telemonitoring
rather than structured telephone support.
Quality of life
Six reviews of telemonitoring in HF reported quality of life
(QOL) as an outcome measure [8,10,23-26]. All of these re-
views described some studies that had demonstrated
improved quality of life (Table 1). There was limited infor-
mation provided about the measures used to evaluate
QOL. Only Klersy et al. [23] reported quality of life in terms
of quality adjusted life years (QALYS). This review calcu-
lated that remote patient monitoring was associated with a
gain of 0.06 QALYs – 0.02 due to reduced mortality and
0.04 due to reduced hospitalisations [23].
Cost
Two reviews of telemonitoring in HF focused on cost as
an outcome measure [23,27]. Both of these reviews con-
cluded that telemonitoring reduced costs compared to
usual care. This reduction in costs was attributed to the
reduction in hospital admissions. Seto [27] also reported
a 3.5% saving in direct patient costs as a result of the re-
duced need for patients to travel to services. Addition-
ally, Seto [27] identified that over half of patients were
willing to make a financial contribution to allow them to
use telemedicine.
Discussion
This systematic review of systematic reviews found that
the use of telemonitoring for patients with hypertension
and HF was associated with multiple benefits. The re-
views of telemonitoring for hypertension demonstrated
that various telemonitoring interventions were able to
effect significant reductions in blood pressure. The re-
views of telemonitoring for HF demonstrated a reduced
risk of mortality [8,10,21,22,24,26], fewer hospitalisations
[8,10,21,22,24-27], reduced health care costs [23,27] and
improved quality of life compared to usual care
[8,10,24-26]. It has been reported in two syntheses of the
effectiveness of telemonitoring across disease groups
that the evidence supporting the efficacy of telemonitor-
ing is most favourable for HF and hypertension com-
pared to other forms of chronic disease [29-31].
A key limitation in the included reviews is the heterogen-
eity of the interventions reported in included studies and
reviews [8,18,19]. Telemonitoring interventions are fre-
quently multi-dimensional, containing a range of elements
including the transmission of physiological data, coaching,
telephone support, video-consultations, nurse interventions
and web based communications [30]. The rapid techno-
logical advancements that have been seen in the last decade




Automated monitoring of signs &
symptoms




Telemonitoring – 4 studies 20% reduction in all-cause mortality (RR 0.80, 95% CI: 0.69 to 0.92; 14 studies)
Structured telephone support – 9
studies
Decrease in all-cause mortality more pronounced with telemonitoring (RR 0.62, 95% CI: 0.45 to
0.85; 4 studies) than with structured telephone support (RR 0.85, 95% CI: 0.72 to 1.01; 9 studies)
Telemonitoring and structured
telephone support – 1 study
Giamouzis
et al. [22]
Telemonitoring Statistically significant reduced all-cause mortality (3 studies).
Inglis et al.
[8]
Telemonitoring (transfer of daily data)
– 11 studies
Telemonitoring reduced all-cause mortality (RR 0.66, 95% CI: 0.54–0.81; 11 studies)
Structured Telephone support – 16
studies
Structured telephone support showed a non-significant trend towards reduced all-cause
mortality (RR 0.88 95% CI: 0.76– 1.01; 15 studies)
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may also impact on the ability to compare older and newer
studies using different technology [30]. Whilst some re-
views reported comparisons between the various types of
telemonitoring interventions, in others it was more difficult
to differentiate the outcomes from the various interven-
tions. Further research needs to tease out the specific as-
pects of telemonitoring interventions that are essential to
improving health outcomes.
A further limitation was the lack of reporting of or use of
unvalidated outcome measures. Whilst some reviews re-
ported the range of outcomes measures used in included
studies, others provided limited data on which to evaluate
how the various outcomes were measured.
A final limitation is that, as a systematic review of re-
views, this paper only included studies that had been re-
ported within systematic reviews. This means that some
more recent research is not included in the analysis. Whilst
this recent literature includes several papers which affirm
the value of telemonitoring [32-35], it also includes some
large trials of telemonitoring in HF and hypertension which
report negative results [36-39]. These divergent findings
highlight the need for future research to more carefully in-
terrogate how and why telemonitoring interventions work
to improve outcomes.
Whilst the specific elements of the interventions that
underpinned the positive outcomes are not clear, it is
postulated that the benefits of telemonitoring reflect a
combination of improved implementation of and adher-
ence to guideline therapies, early identification of com-
plications, and a positive impact on patient psychology
[8,10]. Wotton [31] asserts that telemedicine is effective
as it facilitates integration and case-management within
chronic disease, both strategies well known to improve
guideline adherence and early intervention. Further in-
vestigation into how telemedicine can best be integrated
into existing clinical primary care to enhance case-
management will assist in developing new models of care.
Future research exploring the impact of telemonitoring
on adherence to treatment guidelines and early identifica-
tion of exacerbation, will increase our understanding of
how telemonitoring interventions improve outcomes.
The benefits of telemonitoring can also be attributed
to patient empowerment and its flow on effects [40].
Providing patients with the tools and education to moni-
tor their own symptoms, vital signs, and fluctuating
medication needs, empowers the patient to take an ac-
tive role in their own healthcare. Improved self-
management has long been recognised as a strategy to
enhance outcomes in chronic disease. Given that pa-
tients largely find telemonitoring acceptable and easy to
use [8,10,24,26,41-43], further research focusing on the
impact of telemonitoring on self-management and the
use of telemonitoring as a patient education tool would
inform new models of care [44].
Conclusions
In summary, this systematic review of systematic reviews
found that telemonitoring has the potential to reduce
the burden associated with hypertension and HF in pri-
mary care. However, further well-designed research is re-
quired to facilitate our understanding of how this
intervention improves various outcomes and to allow
the essential components of a telemonitoring interven-
tion to be identified.
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